Search research articles
Contact Us
Filters
Showing results (81-90 of 138) with videos related to
Page
of 14
Sort By:
Blood Advances
|
September 2, 2022
TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones
Lauren C Shaw, Mathilde Poussin, Alba Rodriguez-Garcia, et al.
Plos One
|
December 24, 2011
Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses
Cheryl Lai-Lai Chiang, Andrea R Hagemann, Rachel Leskowitz, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 9, 2004
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
Paul F Robbins, Mark E Dudley, John Wunderlich, et al.
Cancer Research
|
February 15, 2024
Editor's Note: In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
De-Gang Song, Qunrui Ye, Carmine Carpenito, et al.
Cancer Research
|
May 7, 2011
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)
De-Gang Song, Qunrui Ye, Carmine Carpenito, et al.
Human Gene Therapy
|
July 9, 2014
A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes
Evripidis Lanitis, Jenessa B Smith, Denarda Dangaj, et al.
Plos One
|
December 14, 2011
Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody
Denarda Dangaj, Karen L Abbott, Ananda Mookerjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2011
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor
Edmund K Moon, Carmine Carpenito, Jing Sun, et al.
Human Gene Therapy
|
October 24, 2009
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells
Marc R Theoret, Cyrille J Cohen, Azam V Nahvi, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 20, 2007
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
Daniel J Powell, Aloisio Felipe-Silva, Maria J Merino, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 138) with videos related to
Sort By:
Page
of 14
Blood Advances
|
September 2, 2022
TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones
Lauren C Shaw, Mathilde Poussin, Alba Rodriguez-Garcia, et al.
Plos One
|
December 24, 2011
Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses
Cheryl Lai-Lai Chiang, Andrea R Hagemann, Rachel Leskowitz, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 9, 2004
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
Paul F Robbins, Mark E Dudley, John Wunderlich, et al.
Cancer Research
|
February 15, 2024
Editor's Note: In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
De-Gang Song, Qunrui Ye, Carmine Carpenito, et al.
Cancer Research
|
May 7, 2011
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)
De-Gang Song, Qunrui Ye, Carmine Carpenito, et al.
Human Gene Therapy
|
July 9, 2014
A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes
Evripidis Lanitis, Jenessa B Smith, Denarda Dangaj, et al.
Plos One
|
December 14, 2011
Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody
Denarda Dangaj, Karen L Abbott, Ananda Mookerjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2011
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor
Edmund K Moon, Carmine Carpenito, Jing Sun, et al.
Human Gene Therapy
|
October 24, 2009
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells
Marc R Theoret, Cyrille J Cohen, Azam V Nahvi, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 20, 2007
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
Daniel J Powell, Aloisio Felipe-Silva, Maria J Merino, et al.
Page
of 14